OnKure Therapeutics, Inc. OKUR
OnKure Therapeutics, Inc. (Nasdaq: OKUR) is an oncology drug developer. Its lead program, OKI-345, is in Pre-clinical for PI3Kalpha-mutant breast cancer (pan-mutant PI3Kalpha inhibitor). Its next catalyst on record is OKI-345: IND submission (H1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: OKI-345 — IND submission (H1 2027). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| OKI-219 (former lead) | PI3KalphaH1047R-mutant breast cancer; Phase 1 PIKture-01 (Parts A and B enrolled; Parts C and E enrolling as of March 2026 10-K). Described in the 10-Q as the 'former lead product candidate' and excluded from use of 2026 financing proceeds; current status not stated | small molecule | Phase 1 |
| OKI-345 | Breast cancer (next-generation PI3Kalpha pan-mutant inhibitor; IND planned 1H 2027) | small molecule | Pre-clinical |
| OKI-355 | Vascular anomalies (PI3Kalpha pan-mutant inhibitor; IND planned 1H 2027) | small molecule | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.